Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.5050 (7.7%) ($6.5050 - $6.5050) on Fri. May. 13, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.19% (three month average) | RSI | 43 | Latest Price | $6.5050(7.7%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.1% a day on average for past five trading days. | Weekly Trend | TGTX declines -5.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(75%) ARKG(72%) IBB(68%) ARKK(66%) IBUY(59%) | Factors Impacting TGTX price | TGTX will decline at least -3.095% in a week (0% probabilities). VIXM(-51%) VXX(-39%) UUP(-21%) TBT(-13%) USO(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.095% (StdDev 6.19%) | Hourly BBV | 1.4 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-8.74(-234.36%) | Resistance Level | $6.95 | 5 Day Moving Average | $6.22(4.58%) | 10 Day Moving Average | $6.81(-4.48%) | 20 Day Moving Average | $6.95(-6.4%) | To recent high | -42.4% | To recent low | 14.2% | Market Cap | $824m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |